Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NASDAQ:ILMN NASDAQ:ISRG NASDAQ:PODD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$69.07-4.7%$67.13$54.11▼$89.98$27.96B1.455.10 million shs5.55 million shsILMNIllumina$161.38-0.3%$145.95$88.00▼$177.22$24.50B1.51.85 million shs1.79 million shsISRGIntuitive Surgical$402.95-0.9%$437.39$396.68▼$603.88$144.07B1.462.33 million shs2.67 million shsPODDInsulet$138.97-4.7%$162.97$138.79▼$354.88$10.10B1.131.48 million shs1.68 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-4.69%-6.94%-4.20%+3.71%-13.66%ILMNIllumina-0.34%-3.30%+11.75%+28.10%+78.34%ISRGIntuitive Surgical-0.94%-3.26%-8.02%-14.61%-20.89%PODDInsulet-4.66%-6.19%-10.27%-38.37%-54.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$69.07-4.7%$67.13$54.11▼$89.98$27.96B1.455.10 million shs5.55 million shsILMNIllumina$161.38-0.3%$145.95$88.00▼$177.22$24.50B1.51.85 million shs1.79 million shsISRGIntuitive Surgical$402.95-0.9%$437.39$396.68▼$603.88$144.07B1.462.33 million shs2.67 million shsPODDInsulet$138.97-4.7%$162.97$138.79▼$354.88$10.10B1.131.48 million shs1.68 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-4.69%-6.94%-4.20%+3.71%-13.66%ILMNIllumina-0.34%-3.30%+11.75%+28.10%+78.34%ISRGIntuitive Surgical-0.94%-3.26%-8.02%-14.61%-20.89%PODDInsulet-4.66%-6.19%-10.27%-38.37%-54.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.92Moderate Buy$84.8322.82% UpsideILMNIllumina 2.33Hold$142.13-11.93% DownsideISRGIntuitive Surgical 2.67Moderate Buy$573.4242.30% UpsidePODDInsulet 2.74Moderate Buy$240.7873.26% UpsideCurrent Analyst Ratings BreakdownLatest ISRG, PODD, DXCM, and ILMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026DXCMDexCom Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$75.00 ➝ $88.006/12/2026ISRGIntuitive Surgical Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$520.00 ➝ $515.006/11/2026PODDInsulet UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$219.006/11/2026PODDInsulet Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $219.006/10/2026DXCMDexCom UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.006/10/2026DXCMDexCom TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $95.006/10/2026ILMNIllumina JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$125.00 ➝ $185.006/9/2026DXCMDexCom MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$75.00 ➝ $85.006/8/2026PODDInsulet Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$216.006/8/2026DXCMDexCom Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$91.006/5/2026DXCMDexCom Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$85.00 ➝ $90.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.66B5.72$2.64 per share26.17$7.04 per share9.81ILMNIllumina$4.34B5.62$6.69 per share24.12$17.82 per share9.06ISRGIntuitive Surgical$10.06B14.18$9.19 per share43.85$50.52 per share7.98PODDInsulet$2.71B3.55$6.03 per share23.05$21.54 per share6.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$836.30M$2.3429.5222.721.1319.31%33.33%13.19%7/29/2026 (Estimated)ILMNIllumina$850M$5.5029.3427.633.0319.42%31.01%12.22%7/30/2026 (Estimated)ISRGIntuitive Surgical$2.86B$8.2548.8441.083.3128.15%15.98%14.07%7/16/2026 (Estimated)PODDInsulet$247.10M$4.3032.3217.331.1510.44%26.87%12.01%8/6/2026 (Estimated)Latest ISRG, PODD, DXCM, and ILMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/16/2026Q2 2026ISRGIntuitive Surgical$2.48N/AN/AN/A$2.82 billionN/A5/6/2026Q1 2026PODDInsulet$1.19$1.42+$0.23$1.30$729.89 million$761.70 million4/30/2026Q1 2026DXCMDexCom$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion4/30/2026Q1 2026ILMNIllumina$1.05$1.15+$0.10$0.87$1.07 billion$1.09 billion4/21/2026Q1 2026ISRGIntuitive Surgical$2.08$2.50+$0.42$2.28$2.62 billion$2.77 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/AILMNIlluminaN/AN/AN/AN/AN/AISRGIntuitive SurgicalN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.421.951.64ILMNIllumina0.561.751.36ISRGIntuitive SurgicalN/A4.613.59PODDInsulet0.712.491.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%ILMNIllumina89.42%ISRGIntuitive Surgical83.64%PODDInsuletN/AInsider OwnershipCompanyInsider OwnershipDXCMDexCom0.28%ILMNIllumina2.90%ISRGIntuitive Surgical0.60%PODDInsulet0.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom11,000385.87 million384.79 millionOptionableILMNIllumina8,650151.30 million146.91 millionOptionableISRGIntuitive Surgical17,021354.16 million352.04 millionOptionablePODDInsulet5,40069.26 million69.02 millionOptionableISRG, PODD, DXCM, and ILMN HeadlinesRecent News About These CompaniesInsulet (PODD): New Data Shows Its Next-Gen System Delivers Far More Automated InsulinJune 22 at 11:10 AM | insidermonkey.comInsulet Corporation (NASDAQ:PODD) Given Consensus Rating of "Moderate Buy" by AnalystsJune 22 at 2:50 AM | americanbankingnews.comBank of America Securities Maintains Buy Rating on Insulet (PODD) StockJune 21 at 7:51 AM | insidermonkey.comInsulet (PODD) Announces Positive Clinical Trial Results for Next-Generation Omnipod 6 AID SystemJune 21 at 3:51 AM | finance.yahoo.comInsulet (PODD) Announces Positive Clinical Trial Results for Next-Generation Omnipod 6 AID SystemJune 19, 2026 | insidermonkey.comInsulet Corporation Stock: Is PODD Underperforming the Healthcare Sector?June 19, 2026 | barchart.comBTIG Remains a Buy on Insulet (PODD)June 18, 2026 | theglobeandmail.comInsulet Corporation Stock (PODD) Opinions on Diabetes Technology DevelopmentsJune 18, 2026 | quiverquant.comQMan Group plc Has $123.52 Million Stock Holdings in Insulet Corporation $PODDJune 18, 2026 | marketbeat.comArtisan Partners Limited Partnership Sells 9,789 Shares of Insulet Corporation $PODDJune 17, 2026 | marketbeat.comPiper Sandler Keeps Their Buy Rating on Insulet (PODD)June 17, 2026 | theglobeandmail.comMunro Partners Has $7.52 Million Stock Position in Insulet Corporation $PODDJune 16, 2026 | marketbeat.comCastleark Management LLC Acquires 30,460 Shares of Insulet Corporation $PODDJune 13, 2026 | marketbeat.comInsulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting TranscriptJune 12, 2026 | seekingalpha.comAssessing Insulet (PODD) Valuation After New Omnipod Clinical Data And System UpdatesJune 11, 2026 | finance.yahoo.comWhy Insulet (PODD) is a top momentum stock for the long termJune 11, 2026 | msn.comIs Insulet Corporation (PODD) A Good Stock To Buy Now?June 11, 2026 | insidermonkey.comWhy Insulet (PODD) is a Top Momentum Stock for the Long-TermJune 11, 2026 | zacks.comInsulet Corporation $PODD Shares Sold by Allianz Asset Management GmbHJune 11, 2026 | marketbeat.comAnalyst Backs Insulet With Buy Rating, Citing Priced-In Slower Growth Yet Strong EPS Upside PotentialJune 10, 2026 | tipranks.comErste Asset Management GmbH Acquires Shares of 21,889 Insulet Corporation $PODDJune 10, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Non-Pharma Firms That Could Benefit From the GLP-1 TrendBy Nathan Reiff | June 20, 20263 Stocks Doing the Heavy Lifting in Healthcare’s ReboundBy Jessica Mitacek | June 18, 2026ISRG, PODD, DXCM, and ILMN Company DescriptionsDexCom NASDAQ:DXCM$69.07 -3.40 (-4.69%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$68.90 -0.17 (-0.24%) As of 06/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Illumina NASDAQ:ILMN$161.38 -0.55 (-0.34%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$161.15 -0.23 (-0.15%) As of 06/22/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Intuitive Surgical NASDAQ:ISRG$402.95 -3.83 (-0.94%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$403.50 +0.55 (+0.14%) As of 06/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.Insulet NASDAQ:PODD$138.97 -6.79 (-4.66%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$141.34 +2.37 (+1.70%) As of 06/22/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
